Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If you say that leronlimab saved them at a 5-to-1 rate in the first 14 days, then you have to say that it killed them at 3-to-1 rate in days 15-28. You can't say one without saying the other.
Efficacy at day 14 is meaningless if that efficacy is lost at day 28.
If the theory that new short rules being instituted on April 22nd makes it more difficult to short is true, then tomorrow might be their last day to short under the old rules. My guess is that most SEC rules are enforced at the end of the day, not the start of the day. If true, tomorrow could be even better than today.
Has anyone seen any confirmation of any of this anywhere else?
Almost all Covid therapeutic stocks are up today. People are realizing that Covid will be with us forever. Sad but true.
Nicolas Agresti is a gastroenterologist. He is not a scientist. He is not an immunologist. Or a virologist. Or an infectious disease specialist. Nothing remotely relevant to Covid or the pharmaceutical industry. He specializes in colonoscopies. Scott Kelly also zero qualifications. Chris Recknor also zero qualifications. My guess is their value to CytoDyn is that they are willing to overlook corruptness and incompetence in exchange for financial compensation.
He has a 3.8 on health grades.
Nader think he Thanos
SEC thinking he Theranos
CytoDyn soon meet Thanatos
In 4-6 weeks Nader will admit in a CC that no revenue is being generated in the Philippines. And these same posters who are saying how important that revenue is will change their tune and say how irrelevant it is. They will already be onto their next carrot.